Milrinone is a phosphodiesterase inhibitor with positive inotropic and vasodilatory effects. The main mechanism of action is through the inhibition of phosphodiesterase, so that the concentration of cyclic adenosine monophosphate in cardiomyocytes increases, intracellular calcium increases, myocardial contractility is strengthened, and cardiac blood output increases. Clinically, it is mainly used for acute and chronic persistent congestive heart failure caused by various reasons, which is ineffective or ineffective in the treatment of digitalis, diuretics and vasodilators. The usage of Milrinone injection is intravenous injection, first with a loading dose of 25～75μg/kg, 5～10 minutes of slow sedation, and then 0.25～1.0μg/kg per minute to maintain, the maximum daily dose does not exceed 1.13mg/kg. The main adverse reactions are headache, ventricular arrhythmia, weakness, platelet count reduction. The main contraindications are hypotension, tachycardia, renal insufficiency is appropriate to reduce the dosage, allergic to the product is prohibited. It should be noted that during the use of the drug need to monitor the heart rate, heart rate, blood pressure, adjust the dose of the drug if necessary, acute ischemic cardiomyopathy patients should be used with caution, and diuretics, when used in combination, it is easy to lead to water-electrolyte disorders, and it is necessary to pay attention to prevention. Drugs are recommended under the guidance of a physician to clarify the cause of the disease, to avoid blindly using drugs on their own.